公开(公告)号：USRE35694E

公开(公告)日：1997-12-16

申请号：US257472

申请日：1994-06-09

Applicant: Saeid Seyedin ,  Thomas Thomas ,  Hanne Bentz ,  Larry Ellingsworth ,  Rosa Armstrong

Inventor： Saeid Seyedin ,  Thomas Thomas ,  Hanne Bentz ,  Larry Ellingsworth ,  Rosa Armstrong

IPC: A61K38/00 ,  A61L27/22 ,  C07K14/495 ,  C07G7/00 ,  A61K9/00

CPC classification number: C07K14/495 ,  A61L27/227 ,  A61K38/00

Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.

Abstract translation: 描述了在骨中发现并且具有与辅因子组合的体内软骨形成/成骨活性的两种蛋白质。 两种蛋白质在体外TGF-β测定中也与EGF组合有活性。 通过SDS-PAGE，每种分子量约26,000道尔顿。 每个被还原成单个多肽，表明蛋白质可能是同二聚体。 一个具有与人胎盘衍生的TGF-β相同的N-末端序列，而另一个具有与源自人胎盘的TGF-β不同的N-末端序列。 可以使用RP-HPLC或乙酸 - 尿素凝胶电泳将两种蛋白质纯化至均匀。

公开(公告)号：US5416196A

公开(公告)日：1995-05-16

申请号：US943121

申请日：1992-09-10

Applicant: Naofumi Kitabatake ,  Etsushiro Doi ,  Yohichi Kinekawa

Inventor： Naofumi Kitabatake ,  Etsushiro Doi ,  Yohichi Kinekawa

IPC: A23J1/20 ,  A23J3/08 ,  C07G7/00

CPC classification number: A23J1/205 ,  A23J3/08 ,  Y10S530/832 ,  Y10S530/833

Abstract: A transparent adjusted milk whey protein is prepared by a method in which milk whey protein is purified and then the pH of a solution containing the milk whey protein is adjusted to not higher than 4 or not lower than 6. The solution may be heated to a temperature not lower than 55.degree. C. before or after adjusting the pH. Further, an adjusted milk whey product is prepared by a method in which the pH of a solution containing milk whey protein is adjusted to not higher than 4 or not lower than 6 and the solution is heated at a temperature not lower than 55.degree. C. and cooled to a temperature not higher than 10.degree. C., or a method in which the pH of a solution containing purified milk whey protein is adjusted to not higher than 4 or not lower than 6 under such a condition as salt content of the solution is 0 or not higher than 50 mM, and the solution is heated at a temperature not lower than 55.degree. C. and cooled to a temperature not higher than 10.degree. C.

Abstract translation: 通过纯化乳清蛋白的方法制备透明调整乳清蛋白，然后将含有乳清蛋白的溶液的pH调节至不高于4或不低于6。可将溶液加热至 温度不低于55℃，调节pH前后。 此外，通过将含有乳清蛋白的溶液的pH调节为4以上且6以下的方法，将溶液在不低于55℃的温度加热的方法制备调整后的乳清产品。 并冷却至不高于10℃的温度，或其中将含有纯化乳清蛋白的溶液的pH调节至不高于4或不低于6的方法，在溶液的盐含量 为0或不高于50mM，将溶液在不低于55℃的温度下加热并冷却至不高于10℃的温度。

公开(公告)号：US5376368A

公开(公告)日：1994-12-27

申请号：US186762

申请日：1994-01-25

Applicant: Thomas R. Ulich

Inventor： Thomas R. Ulich

IPC: A61K38/20 ,  A61K37/02 ,  C07G7/00

CPC classification number: A61K38/204

Abstract: A method for treatment of inflammation, comprising the step of administering to a patient in need thereof an effective, inflammation-inhibiting amount of a composition comprising IL-6, or IL-6 and TGF.beta. together in a weight ratio of from about 5:95 to 95:5, preferably from about 20:80 to 80:20. Also disclosed is a composition for treatment of inflammation, comprising as active ingredients IL-6 and TGF.beta. in a weight ratio of from about 5:95 to about 95:5, optionally comprising a carrier in combination with the active ingredients, and a method of reducing migration of neutrophils into tissue of an animal which has received an inflammatory stimulus, comprising the step of administering to the tissue an effective neutrophil-migration-inhibiting amount of a composition as defined above.

Abstract translation: 一种用于治疗炎症的方法，包括以下步骤：向有需要的患者施用有效的炎症抑制量的包含IL-6或IL-6和TGFβ的组合物，其重量比为约5： 95至95:5，优选约20:80至80:20。 还公开了用于治疗炎症的组合物，其包含重量比为约5:95至约95:5的活性成分IL-6和TGFβ，任选地包含与活性成分组合的载体，以及方法 减少嗜中性粒细胞迁移到已经接受炎症刺激的动物的组织中，包括向组织施用有效的中性粒细胞迁移抑制量的上述组合物的步骤。

公开(公告)号：US4778846A

公开(公告)日：1988-10-18

申请号：US10660

申请日：1987-02-04

Applicant: Robert D. Sitrin ,  Kenneth M. Snader ,  Gail F. Wasserman

Inventor： Robert D. Sitrin ,  Kenneth M. Snader ,  Gail F. Wasserman

IPC: G01N33/543 ,  G01N33/94 ,  A23J1/00 ,  C07G7/00 ,  C08L89/00

CPC classification number: G01N33/54353 ,  G01N33/543 ,  G01N33/9446 ,  Y10S530/81 ,  Y10S530/811 ,  Y10S530/812 ,  Y10S530/813 ,  Y10S530/814 ,  Y10S530/815 ,  Y10S930/19

Abstract: A novel process for the isolation and purification of vancomycin class antibiotics which utilized affinity chromatography by the formation of a sorption complex between the antibiotic and an immobilizing ligand selected from -D-alanyl-D-alanine or -X-D-alanyl-D-alanine, wherein X is an amino acid radical and the novel affinity chromatography sorbent employed therein are disclosed.

Abstract translation: 用于分离和纯化万古霉素类抗生素的新方法，其通过在抗生素和选自D-丙氨酰-D-丙氨酸或-XD-丙氨酰-D-丙氨酸的固定配体之间形成吸附配合物而利用亲和层析， 其中X是氨基酸基团，并且公开了其中使用的新的亲和层析吸附剂。

公开(公告)号：US4748157A

公开(公告)日：1988-05-31

申请号：US827209

申请日：1986-02-04

Applicant: Masakazu Iwai ,  Kazumasa Yokoyama ,  Tsunekazu Fukushima

Inventor： Masakazu Iwai ,  Kazumasa Yokoyama ,  Tsunekazu Fukushima

IPC: A61K38/00 ,  C07K16/18 ,  A61K37/00 ,  C07G7/00

CPC classification number: C07K16/18 ,  A61K38/00 ,  Y10S514/925 ,  Y10S514/926 ,  Y10S514/927 ,  Y10S514/929 ,  Y10S530/866

Abstract: Fab or Fc fragment of human IgG which is obtainable by enzymatic digestion of the human IgG is reduced by a reducing agent to sever an interchain of disulfide bonds therein and then blocked the SH radicals formed with alkyl group which may contain other group. The resulting alkylated Fab and Fc fragments display therapeutic and prophylactic action for gastrointestinal ulcers by the oral or parenteral administration.

Abstract translation: 通过人IgG的酶消化可获得的人IgG的Fab或Fc片段被还原剂还原，以切断其中二硫键的链间，然后封闭由可能含有其它基团的烷基形成的SH自由基。 所得到的烷基化Fab和Fc片段通过口服或肠胃外给药显示对胃肠溃疡的治疗和预防作用。

公开(公告)号：US4730050A

公开(公告)日：1988-03-08

申请号：US34784

申请日：1987-04-03

Applicant: Richard A. G. Smith

Inventor： Richard A. G. Smith

IPC: A61K38/16 ,  A61K38/46 ,  A61K39/395 ,  A61P7/02 ,  C07D213/71 ,  C12N9/64 ,  C12N9/70 ,  C12N11/06 ,  A61K37/48 ,  C07C103/52 ,  C07G7/00

CPC classification number: C07D213/71 ,  C12N11/06

Abstract: A derivative of a fibrinolytic enzyme in which the catalytic site on the enzyme which is responsible for fibrinolytic activity is blocked by a human protein attached thereto by way of a reversible linking group.

公开(公告)号：US4719290A

公开(公告)日：1988-01-12

申请号：US614005

申请日：1984-05-25

Applicant: Willie M. Curry ,  David L. Farb

Inventor： Willie M. Curry ,  David L. Farb

IPC: A61K38/00 ,  C07K16/06 ,  C07K16/12 ,  C07G7/00 ,  A61K35/10 ,  A61K39/00

CPC classification number: C07K16/1214 ,  C07K16/065 ,  A61K38/00 ,  Y10S530/861

Abstract: An intravenous immune globulin preparation having at least 99% pure globulin protein and an anticomplement activity of less than 0.10 C'50 units/mg IgG prepared by: precipitating impurities from Cohn Fraction II in an aqueous-alcohol medium at defined temperature and pH, removing the precipitated impurities, stabilizing the diluted solution with albumin, concentrating the solution and removing the alcohol therefrom. Also prepared by this method, an intravenous, hyperimmune globulin preparation having increased antibody titers to sixteen serospecific strains of Pseudomonas aeruginosa.

Abstract translation: 一种具有至少99％的纯球蛋白蛋白和小于0.10C'50单位/ mg IgG的抗补体活性的静脉内免疫球蛋白制剂，其通过以下步骤制备：通过在规定的温度和pH下在含水醇介质中沉淀Cohn级分II的杂质，除去 沉淀的杂质，用白蛋白稳定稀释溶液，浓缩溶液并从中除去醇。 还通过该方法制备了具有增加的抗体滴度的十六个铜绿假单胞菌血清特异性菌株的静脉内，超免疫球蛋白制剂。

公开(公告)号：US4698387A

公开(公告)日：1987-10-06

申请号：US665354

申请日：1984-10-26

Applicant: Karl-Heinz Schmidt ,  Wolfgang Feller

Inventor： Karl-Heinz Schmidt ,  Wolfgang Feller

IPC: A61K38/16 ,  A61K38/00 ,  A61K47/48 ,  A61P7/08 ,  C07K14/805 ,  C07K17/02 ,  C07G7/00 ,  A61K31/71 ,  A61K37/00 ,  C07C103/52

CPC classification number: A61K47/48215 ,  A61K47/4823 ,  C07K14/805 ,  C07K17/02 ,  A61K38/00 ,  Y10S530/813 ,  Y10S530/816

Abstract: The invention relates to an allosterically active conjugate composition comprising one or more hemoglobin tetramers and one or more adducts of a physiologically safe macromolecular agent covalently linked to one or more ligands, such that the adduct is bound to the allosteric binding site of the hemoglobin in a reversible, non-covalent manner; the invention also relates to methods for producing such conjugate compositions; and to blood substitutes or plasma extenders containing such conjugates.

Abstract translation: 本发明涉及包含一种或多种血红蛋白四聚体和与一种或多种配体共价连接的生理上安全的大分子试剂的一种或多种加合物的变构活性缀合物组合物，使得加合物结合于血红蛋白的变构结合位点 可逆的，非共价的; 本发明还涉及生产这种缀合物组合物的方法; 以及含有这种缀合物的血液代用品或血浆增量剂​​。

公开(公告)号：US4620908A

公开(公告)日：1986-11-04

申请号：US622019

申请日：1984-06-18

Applicant: John P. Van Duzer

Inventor： John P. Van Duzer

IPC: A61L2/00 ,  C07G7/00 ,  A61K41/00 ,  B01J19/08

CPC classification number: A61L2/0035

Abstract: A method for destroying microbial contamination, such as viral and bacterial contamination and mycoplasma contamination, in protein material, and particularly tissue and serum from animals and human beings. The method comprises the reducing of the temperature of the protein material, in a state other than a lyophilized state, to at least the freezing point and preferably to the eutectic point. The method comprises reducing the temperature of lyophilized protein to at least a temperature of -3 degrees C., or colder. Thereafter, gamma radiation is applied in an amount sufficient, at least 5,000 rads and preferably at least 600,000 rads, to destroy substantially all microbial contamination in the protein material without significantly reducing the protein efficacy.

Abstract translation: 一种破坏微生物污染的方法，如病毒和细菌污染以及支原体污染，蛋白质材料，特别是来自动物和人类的组织和血清。 所述方法包括将蛋白质材料的温度在冻干状态以外的状态下降低至至少冰点，优选降低至共晶点。 该方法包括将冻干蛋白的温度降至至少-3摄氏度或更低的温度。 此后，以足够的量施加γ射线，至少5,000rad，优选至少600,000rad，以破坏蛋白质材料中的所有微生物污染物，而不显着降低蛋白质功效。

公开(公告)号：US4533496A

公开(公告)日：1985-08-06

申请号：US608283

申请日：1984-05-08

Applicant: Charles Lewis, Jr. ,  Jitka V. Olander ,  William R. Tolbert

Inventor： Charles Lewis, Jr. ,  Jitka V. Olander ,  William R. Tolbert

IPC: G01N33/577 ,  A61K39/395 ,  C07K1/16 ,  C07K1/30 ,  C07K1/36 ,  C07K16/00 ,  C07K17/08 ,  C12N15/00 ,  C12N15/02 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  C07G7/00

CPC classification number: C07K16/00 ,  Y10S530/809

Abstract: Monoclonal antibodies are isolated from spent culture medium of the in vitro growth of hybridoma cells by treating said spent cell culture medium or a concentrate thereof with a water-insoluble, cross-linked polyelectrolyte copolymer.

Abstract translation: 通过用水不溶性的交联聚电解质共聚物处理所述废细胞培养基或其浓缩物，从杂交瘤细胞体外生长的废培养基中分离单克隆抗体。